Cord Blood-derived NK Cells
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 94 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Adoptive Cellular Therapy, Chemotherapy, Natural Killer (NK) Cells (Allogeneic)
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1562
- NCT Identifier
- NCT05092451
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.